207 related articles for article (PubMed ID: 25933185)
41. Adjuvant therapy of pancreatic cancer.
Chaulagain CP; Ng J; Wazer D; Saif MW
JOP; 2012 Jul; 13(4):349-53. PubMed ID: 22797387
[TBL] [Abstract][Full Text] [Related]
42. Pancreatic cancer: what the oncologist can offer for palliation.
Moore MJ
Can J Gastroenterol; 2002 Feb; 16(2):121-4. PubMed ID: 11875597
[TBL] [Abstract][Full Text] [Related]
43. [Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer].
Ryu JK
Korean J Gastroenterol; 2015 Sep; 66(3):150-3. PubMed ID: 26387697
[TBL] [Abstract][Full Text] [Related]
44. Pancreatic cancer.
Kamisawa T; Wood LD; Itoi T; Takaori K
Lancet; 2016 Jul; 388(10039):73-85. PubMed ID: 26830752
[TBL] [Abstract][Full Text] [Related]
45. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.
Wang MT; Fer N; Galeas J; Collisson EA; Kim SE; Sharib J; McCormick F
Nat Commun; 2019 Jul; 10(1):3055. PubMed ID: 31296870
[TBL] [Abstract][Full Text] [Related]
46. Chemotherapy for advanced pancreatic cancer.
Chua YJ; Cunningham D
Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):327-48. PubMed ID: 16549331
[TBL] [Abstract][Full Text] [Related]
47. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
Schultheis B; Reuter D; Ebert MP; Siveke J; Kerkhoff A; Berdel WE; Hofheinz R; Behringer DM; Schmidt WE; Goker E; De Dosso S; Kneba M; Yalcin S; Overkamp F; Schlegel F; Dommach M; Rohrberg R; Steinmetz T; Bulitta M; Strumberg D
Ann Oncol; 2017 Oct; 28(10):2429-2435. PubMed ID: 28961832
[TBL] [Abstract][Full Text] [Related]
48. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.
Collisson EA; Sadanandam A; Olson P; Gibb WJ; Truitt M; Gu S; Cooc J; Weinkle J; Kim GE; Jakkula L; Feiler HS; Ko AH; Olshen AB; Danenberg KL; Tempero MA; Spellman PT; Hanahan D; Gray JW
Nat Med; 2011 Apr; 17(4):500-3. PubMed ID: 21460848
[TBL] [Abstract][Full Text] [Related]
49. What's new in pancreatic cancer treatment?
Fung MC; Sakata T
J Hepatobiliary Pancreat Surg; 2002; 9(1):61-75. PubMed ID: 12021899
[TBL] [Abstract][Full Text] [Related]
50. New developments in chemotherapy for patients with advanced pancreatic cancer.
Rothenberg ML
Oncology (Williston Park); 1996 Sep; 10(9 Suppl):18-22. PubMed ID: 8884803
[TBL] [Abstract][Full Text] [Related]
51. Systemic treatment of pancreatic cancer revisited.
Ducreux M; Seufferlein T; Van Laethem JL; Laurent-Puig P; Smolenschi C; Malka D; Boige V; Hollebecque A; Conroy T
Semin Oncol; 2019 Feb; 46(1):28-38. PubMed ID: 30638624
[TBL] [Abstract][Full Text] [Related]
52. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients.
Hong JY; Nam EM; Lee J; Park JO; Lee SC; Song SY; Choi SH; Heo JS; Park SH; Lim HY; Kang WK; Park YS
Cancer Chemother Pharmacol; 2014 Jan; 73(1):125-30. PubMed ID: 24162380
[TBL] [Abstract][Full Text] [Related]
53. Adjuvant therapy for pancreatic cancer: back to the future.
Regine WF; Abrams RA
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):59-63. PubMed ID: 9747820
[TBL] [Abstract][Full Text] [Related]
54. Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value.
Kwon MJ; Jeon JY; Park HR; Nam ES; Cho SJ; Shin HS; Kwon JH; Kim JS; Han B; Kim DH; Choi YL
Pancreas; 2015 Apr; 44(3):484-92. PubMed ID: 25513781
[TBL] [Abstract][Full Text] [Related]
55. Pancreatic cancer heterogeneity and response to Mek inhibition.
Pedersen K; Bilal F; Bernadó Morales C; Salcedo MT; Macarulla T; Massó-Vallés D; Mohan V; Vivancos A; Carreras MJ; Serres X; Abu-Suboh M; Balsells J; Allende E; Sagi I; Soucek L; Tabernero J; Arribas J
Oncogene; 2017 Oct; 36(40):5639-5647. PubMed ID: 28581516
[TBL] [Abstract][Full Text] [Related]
56. Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
Roehrig S; Wein A; Albrecht H; Konturek PC; Reulbach U; Männlein G; Wolff K; Ostermeier N; Hohenberger W; Hahn EG; Boxberger F
Med Sci Monit; 2010 Mar; 16(3):CR124-131. PubMed ID: 20190682
[TBL] [Abstract][Full Text] [Related]
57. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
58. Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.
Haas M; Ormanns S; Baechmann S; Remold A; Kruger S; Westphalen CB; Siveke JT; Wenzel P; Schlitter AM; Esposito I; Quietzsch D; Clemens MR; Kettner E; Laubender RP; Jung A; Kirchner T; Boeck S; Heinemann V
Br J Cancer; 2017 May; 116(11):1462-1469. PubMed ID: 28449008
[TBL] [Abstract][Full Text] [Related]
59. Systemic Chemotherapy in Advanced Pancreatic Cancer.
Lee HS; Park SW
Gut Liver; 2016 May; 10(3):340-7. PubMed ID: 27114434
[TBL] [Abstract][Full Text] [Related]
60. [Second line chemotherapy for pancreatic cancer].
Park JY
Korean J Gastroenterol; 2011 Apr; 57(4):207-12. PubMed ID: 21519173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
